🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Nutex Health Inc. NUTX R2KR3KPHARMA

Healthcare · Medical Care Facilities · United States
https://www.nutexhealth.com
Company Profile ↓
$193.24
+83.71% 1Y
Mkt Cap$1.32B
P/E7.49
P/B3.25
52W High$197.68
52W Low$80.92
Book Value$49.81
EPS (TTM)$25.80

Company Overview

Nutex Health Inc. operates as a healthcare services and operations company in the United States. It operates through three segments: Hospital, Population Health Management (PHM), and Real Estate. The Hospital segment develops and operates a network of micro hospitals, specialty hospitals, and hospital outpatient departments that offer healthcare services, including emergency room care, inpatient care, and behavioural health. It also provides imaging services, such as CT scan, X-ray, MRI, ultrasound, etc.; laboratory services; and onsite inpatient pharmacies. The PHM segment provides management, administrative, and other support services to its affiliated hospitals and physician groups by establishing and operating provider networks, such as independent physician associations (IPAs); and a cloud-based technology platform for IPAs. The Real Estate segment owns and leases land and hospital buildings. Nutex Health Inc. was founded in 2011 and is headquartered in Houston, Texas.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 53.6%, reflecting efficient use of shareholder capital.

Healthy Capital Returns

Return on capital employed stands at 36.2%.

Consistent Profit Growth

Net profit has compounded at 38.9% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 58.6% CAGR over the past five years.

Reasonable Valuation

Trades at a P/E of 7.5, below the sector median of 25.2.

Healthy Margins

Operating margin of 37.5% supports profitability.

Recent Developments

  • Dec 2025 Revenue of $875.26M (+82.4% YoY); net profit $70.79M.
  • Trailing 12 Months Year-on-year growth — revenue +2.2%, earnings +95.9%.
  • 5-Year Trend Long-term compounding — revenue CAGR 58.6%, profit CAGR 38.9%.

Growth & Price Performance

Compounded Sales Growth

5 Years:58.62%
1 Year:2.20%

Compounded Profit Growth

5 Years:38.89%
1 Year:95.90%

Stock Price Performance

1 Year:+83.71%
6 Months:+114.05%
3 Months:+45.74%
1 Month:+27.19%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 96% of range
$80.92 $197.68
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)58.53 · Neutral
Price Performance
1M+27.19%
3M+45.74%
6M+114.05%
1Y+83.71%
Valuation vs Sector

P/E of 7.49 is below the sector median of 25.17 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Strong return on equity of 53.6%.
  • Healthy ROCE of 36.2%.
  • Compounding revenue at 58.6% over 5 years.
  • Profit CAGR of 38.9% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
7.49
Industry PE
25.17
Forward P/E
9.51
PEG Ratio
-
Book Value
$49.81
Price to Book
3.25
P/S
1.26
EV/EBITDA
3.10
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
58.62%
Profit 5Y
38.89%
Revenue (YoY)
2.20%
Earnings (YoY)
95.90%

Profitability & Returns

ROCE
36.24%
ROE
53.65%
ROA
28.59%
Profit Margin
10.95%
Op Margin
37.54%
Gross Margin
50.58%
EPS (Latest Qtr)
$9.38
EPS (TTM)
$25.80

Balance Sheet & Liquidity

Debt/Equity
0.79
Quick Ratio
3.00
Current Ratio
3.14
Debt
$349.09M
Total Assets
$964.63M
Current Assets
-
Working Capital
-

Ownership

Promoter Holding
29.23%
Chg in Prom Hold
0.14%
FII / Inst Holding
43.92%
Chg in FII Hold
0.02%

Financial Snapshot

Enterprise Value
$1.32B
Total Revenue (TTM)
$879.95M
EBITDA
$414.16M
Free Cash Flow
$168.75M
Operating Cash Flow
$272.68M
Shares Outstanding
6.85M
Gross Margin
50.58%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 NUTX Nutex Health Inc. R2KR3KPHARMA 193.24 7.49 $1.32B 0.00% 36.24% 53.65% 58.62% 38.89%
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,149.36 38.57 $1.02T 0.58% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 275.23 31.97 $663.28B 2.09% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 256.46 72.45 $453.19B 2.84% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 150.33 120.26 $371.29B 2.65% - 34.70% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 397.14 25.54 $356.47B 2.33% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 159.99 24.20 $304.10B 3.03% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 162.70 24.36 $252.33B 1.98% 15.97% 21.96% 9.82% 45.96%
9 AMGN Amgen Inc. NDXSPXR3KPHARMA 437.23 27.14 $235.98B 2.49% 13.95% 91.47% 5.51% 5.55%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Sep 2014Mar 2015Jun 2015Sep 2015Mar 2016Jun 2016Sep 2016Mar 2017Jun 2017Sep 2017Mar 2018Jun 2018Sep 2018Mar 2019Jun 2019Sep 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue ------------------------29.00M---------211.79M243.99M267.80M151.68M216.49M-
Cost of Revenue ----------------------------------93.45M119.06M112.92M105.54M124.75M-
Gross Profit 153.95K164.72K180.32K186.34K400.56K004.17K-9.84K11.06K-3.74K-4.17K14.75K43.68K-1.79K111.26K266.50K113.73K139.14K426.87K29.14M76.01M35.82M6.64M-23.71M530.32K4.85M9.65M7.07M13.21M10.16M22.56M21.92M-118.34M124.92M154.88M46.14M91.73M141.28M
Operating Expenses ----------------------------------37.68M91.25M24.51M15.22M10.46M-
Operating Income -184.34K-143.19K-86.80K-121.83K-161.94K-64.51K-75.70K-163.21K-1.25M-711.94K-411.97K-489.01K-367.01K-925.91K-374.71K-906.13K-939.91K645.56K1.78M-4.15M27.60M74.46M29.24M-1.38M-428.68M-5.78M-4.45M-362.54K-821.23K-26.14M1.45M5.30M9.66M-80.66M33.68M130.37M30.92M81.27M121.72M
EBITDA ----------------------------------82.43M34.66M134.39M36.06M86.73M-
Interest Expense ----------------------------------6.12M5.68M5.45M4.98M4.68M-
Pretax Income ----------------------------------71.22M23.73M123.94M25.89M76.56M-
Tax Provision ----------------------------------20.41M7.59M27.14M9.29M13.80M-
Net Income -185.76K-144.90K-51.65K-74.85K-238.87K-96.05K216.67K-242.07K-1.65M6.33M-610.03K-726.25K-608.52K-968.16K-570.37K-857.63K-1.12M227.31K1.76M-4.48M29.68M74.49M21.44M-19.28M-412.19M-14.75M-5.15M-3.48M-5.54M-31.62M-364.00K-364.00K-8.79M-21.22M-17.70M55.44M11.83M46.81M65.84M
Diluted EPS --------------------0.050.090.04-0.03-0.62-0.02-0.12-0.79-1.25-7.47-0.08-0.07-1.7211.123.33-2.957.76-6.529.38
R&D Expense -------------181.25K-107.76K114.88K314.25K73.83K76.72K59.63K72.27K73.75K-----------------

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 874.77K1.78M1.59M1.46M1.07M474.68K023.17K1.37M1.37M274.03M331.53M219.29M247.65M479.95M875.26M
Cost of Revenue ------------203.87M212.87M283.69M430.98M
Gross Profit 483.19K1.02M810.38K965.17K603.28K466.63K0-7.32K859.36K535.98K157.61M179.28M15.42M34.77M196.26M444.28M
Operating Expenses ------------20.00M36.28M58.48M168.66M
Operating Income -1.35M-844.58K-1.57M-727.38K-723.43K-532.99K-448.60K-5.69M-840.40K-6.90M153.17M170.26M-4.58M-1.51M137.78M275.62M
EBITDA -------------394.03M-14.58M148.73M287.54M
Interest Expense ------------12.49M16.32M19.93M22.23M
Pretax Income -------------419.65M-48.49M109.83M244.78M
Tax Provision ------------13.09M-5.07M15.02M64.42M
Net Income 158.14K-383.39K-1.62M250.49K-684.34K83.81K-7.43M582.06K-950.13K-7.12M105.97M132.59M-424.78M-45.79M52.10M70.79M
Diluted EPS ----------0.180.22-100.50-10.509.7110.48
R&D Expense --------545.22K768.10K557.26K285.88K----

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets 2.34M1.89M745.92K1.07M280.79K7.64M510.83K3.33M449.43K6.69M169.86K394.65M431.75M398.25M655.32M918.52M
Total Equity -1.60M305.70K556.19K-4.49K1.56M-5.87M-997.22K-1.50M1.86M-1.13M114.65M95.86M61.45M132.44M329.45M
Cash & Equivalents 465.55K224.80K104.72K26.87K126.83K122.29K10.52K9.45K119.27K1.07M26.93K36.12M34.26M22.00M40.64M185.57M
Long Term Debt --------300.00K0078.82M23.05M26.31M22.47M29.17M
Total Liabilities ----285.28K6.08M6.38M-1.95M4.83M1.30M203.07M311.42M319.14M466.79M495.09M
Current Liabilities 351.62K288.58K440.22K515.15K285.28K6.08M6.38M959.78K1.04M4.61M1.15M37.69M54.86M58.31M154.22M157.91M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -1.64M-659.14K-518.69K-183.15K159.20K44.91K-274.22K-714.62K-480.05K-4.04M86.67M173.43M50.61M1.26M23.15M248.12M
Investing Cash Flow 1.22M413.39K417.74K1.80K-4.74K1.83K-9.99K2.05K-116.96K-748.20K-61.19M-36.98M-4.34M-11.24M-5.61M-5.24M
Financing Cash Flow 22.89K--19.13K103.50K-54.50K-51.28K172.44K711.50K704.57K5.73M-7.97M-125.85M-48.13M-2.27M1.09M-97.95M
Capital Expenditure 5.69K19.39K8.06K-2.03K1.80K---0-84.00K-61.19M-36.93M-14.63M-9.50M-2.30M-2.53M
Free Cash Flow -1.63M-639.75K-510.63K-161.23K46.70K---480.05K-4.12M25.48M136.51M35.97M-8.24M20.85M245.60M
Share Buybacks -------------005.00M

Ratios (Annual)

Figures in %.

Metric Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % 55.2%57.1%50.8%66.1%56.5%98.3%--31.6%62.9%39.2%57.5%54.1%7.0%14.0%40.9%50.8%
Operating Margin % -153.9%-47.3%-98.7%-49.8%-67.7%-112.3%--24,574.5%-61.5%-504.8%55.9%51.4%-2.1%-0.6%28.7%31.5%
Net Margin % 18.1%-21.5%-101.9%17.1%-64.0%17.7%-2,512.6%-69.5%-520.8%38.7%40.0%-193.7%-18.5%10.9%8.1%
ROE % --23.9%-531.2%45.0%15,238.1%5.4%126.6%-58.4%63.5%-382.9%-9,346.5%115.6%-443.1%-74.5%39.3%21.5%
ROCE % -67.8%-52.7%-514.6%-130.8%16,108.5%-34.1%7.6%-240.3%141.3%-331.3%-15,569.7%47.7%-1.2%-0.4%27.5%36.2%

Shareholding Pattern

Insiders
29.23%
Institutions
43.92%
Public Float
62.06%

Top Institutional Holders

#Holder% HeldSharesValue
1 Pertento Partners LLP 6.59% 451.31K $85.41M
2 Blackrock Inc. 5.95% 407.35K $77.09M
3 American Century Companies Inc 3.47% 237.41K $44.93M
4 Vanguard Capital Management LLC 3.15% 215.92K $40.86M
5 Geode Capital Management, LLC 1.93% 132.05K $24.99M
6 State Street Corporation 1.91% 130.84K $24.76M
7 Shaw D.E. & Co., Inc. 1.42% 97.45K $18.44M
8 UBS Group AG 1.14% 77.91K $14.74M
9 Winmill & Co. Inc 0.95% 65.35K $12.37M
10 Focus Partners Wealth 0.89% 60.88K $11.52M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for NUTX

Google News hu, 27 Aug 2026

Is Nutex Health (NUTX) Stock Still A Bargain Or Fully Priced? - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxONEFBejVXTjJxaEdkNkc4bFN3MDFIQUNDUjNCQTBtMGEybktsM2dPMXdWYkZaOU5OSXdHdXVQN3FWeFhUcEtsMXA5a1JpWmhNRGQzNjlCSDlIZ25OUzd5NWlmXzZ4TFk5U0Rfa2tVMEwzaDFMODl2dldLcS1IUTdvakNESm95YWFoX2Fzb0…

Google News Sun, 06 Sep 2026

How (NUTX) Movements Inform Risk Allocation Models - Stock Traders Daily

<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxNWVVlZ3VaYUY3UkxvdG1VT3dFdm1sczJ0Vkh6U05LUHdZTkRTU0V6WWJqMzM2VWIxYXpsUnZnUzRkNmtBVkJYTU1CNU53UXgzZHpSVktzSGZGVmkwRzRybGxwTTFHMDBNT2JTamhmaUdmMEZjYVVfTE0tbk5BMkVkaV9zMGVYOXQtd0Uydk…

Google News Fri, 05 Jun 2026

Nutex Health or HCA Healthcare: Which Stock Has More Upside? - Trefis

<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxOakoxeU1qTWtqQmVRTmtuM0tjZlpSUFhubXd3TE80bW9leTVKSk1jNW5iVmw2a3NWSU9aRGJOLUpLczNvZlNDZkc2MGZIN3hjaE91OHhVenJWUzNvWGhNcHZSVVVlaEg1QlBDVUdVaXBKb0FXWGxLQ3M0bHhpS25UUUZZTzNLUi1lSDhDVk…

Google News ue, 25 Aug 2026

Wall Street Analysts See a 47.12% Upside in Nutex Health (NUTX): Can the Stock Really Move This High? - qz.com

<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxOck81VUQzQk8zQjMyRkxrNkl1TWlSQ1RuZEhvZmxZUHd2M2dHdjBHZWE0WGJ2TFFNdGZaZGVteENUMWFlZFhEWk50WERQV2hXNXJiR3BxQzF4d3hfdHFwRlA2SzA0dEhNUzNxZ3NVc3RHeWp5RUUxM2ZNb1FfdWJrdUdWU2RYdE05WnluS1…

Google News Mon, 10 Aug 2026

Nutex Health jumps 21%, continuing post-earnings run (NUTX:NASDAQ) - Seeking Alpha

<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxNUUZIMzFYN3BYMkF0Ymw0cjd3S3dnRUhHSFRrWTFmbDY1bGY2YzhINzdkMzR3ZVJiWGd3QkZaek81SzB1SExyMUtmci1yMy15Y1QwelpCVkY5emZXVlluUTRfekFyN2FKal9SVlhGZnFIN3VBWW5kM1RQSWRLUWR5ZVNPSmdONkZka2w1am…

Google News ue, 26 May 2026

NUTX - Nutex Health Inc Stock Price and Quote - Finviz

<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE1ubzVpN2xSSG5ZYVF3RVl0WDBrRHN1UElpeWZJd05LZlRtRkRwZG9CMUYyU3hUZ2VGX0w0UzhsNVBZSHFKUmc?oc=5" target="_blank">NUTX - Nutex Health Inc Stock Price and Quote</a>&nbsp;&nbsp;<font color…

NUTX — Frequently Asked Questions

What is the current share price of Nutex Health Inc. (NUTX)?

As of 2026-09-07 16:24 PDT, Nutex Health Inc. (NUTX) trades at $193.24 on NasdaqCM. Its 52-week range is $80.92 to $197.68.

What is the market capitalisation of NUTX?

Nutex Health Inc. (NUTX) has a market capitalisation of $1.32B on NasdaqCM.

What is the P/E ratio of NUTX?

NUTX trades at a trailing price-to-earnings (P/E) ratio of 7.49. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 3.25.

What is the return on equity (ROE) of NUTX?

NUTX has a return on equity (ROE) of 53.65%. Its return on capital employed (ROCE) is 36.24%.

Is NUTX a good stock to buy?

This page provides a data-driven analysis of Nutex Health Inc. (NUTX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space